BR112017021608A2 - ésteres de glicosaminoglicano, processos para sua preparação e seu uso em formulações oftálmicas - Google Patents
ésteres de glicosaminoglicano, processos para sua preparação e seu uso em formulações oftálmicasInfo
- Publication number
- BR112017021608A2 BR112017021608A2 BR112017021608A BR112017021608A BR112017021608A2 BR 112017021608 A2 BR112017021608 A2 BR 112017021608A2 BR 112017021608 A BR112017021608 A BR 112017021608A BR 112017021608 A BR112017021608 A BR 112017021608A BR 112017021608 A2 BR112017021608 A2 BR 112017021608A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- processes
- ophthalmic formulations
- glycosaminoglycan
- glycosaminoglycan esters
- Prior art date
Links
- 229920002683 Glycosaminoglycan Polymers 0.000 title abstract 2
- 150000002148 esters Chemical class 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 229930003362 apo carotenoid Natural products 0.000 abstract 1
- 150000002768 apo carotenoid derivatives Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITFI20150102 | 2015-04-07 | ||
| PCT/IB2016/051960 WO2016162809A1 (en) | 2015-04-07 | 2016-04-07 | Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017021608A2 true BR112017021608A2 (pt) | 2018-07-03 |
Family
ID=53719816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017021608A BR112017021608A2 (pt) | 2015-04-07 | 2016-04-07 | ésteres de glicosaminoglicano, processos para sua preparação e seu uso em formulações oftálmicas |
Country Status (12)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000012535A1 (it) * | 2020-05-27 | 2021-11-27 | Stefano Colombo | Composizione oftalmica a base di acido ialuronico per la protezione dai danni causati dall’inquinamento ambientale |
| WO2022094695A1 (en) | 2020-11-03 | 2022-05-12 | Institut National De La Recherche Scientifique | A method and a system for compressed ultrafast tomographic imaging |
| CN116284495B (zh) * | 2023-03-20 | 2024-08-30 | 润辉生物技术(威海)有限公司 | 全反式维甲酸低分子透明质酸酯衍生物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| IT1281877B1 (it) * | 1995-05-10 | 1998-03-03 | Fidia Advanced Biopolymers Srl | Sali di metalli pesanti di succinil derivati dell'acido ialuronico e loro impiego come potenziali agenti terapeutici |
| ITTS20010017A1 (it) * | 2001-07-17 | 2003-01-17 | Ct Ricerche Polytech Soc Coop | Esteri polisaccaridici di acido retinoico. |
| ITMI20022745A1 (it) * | 2002-12-23 | 2004-06-24 | Coimex Scrl United Companies | Esteri misti dell'acido ialuronico ad attivita' citostatica e prodifferenziante e procedimento per la loro produzione. |
| ITMI20030043A1 (it) * | 2003-01-14 | 2004-07-15 | Coimex S C R L United Companies | Uso di esteri retinoici dell'acido ialuronico in cellule |
| WO2005077176A1 (en) * | 2004-02-11 | 2005-08-25 | The Trustees Of Columbia University In The City Of New York | Anthocyanin compounds and methods of use thereof |
| ITMI20040347A1 (it) * | 2004-02-26 | 2004-05-26 | Pharma Medical Ltd | Nuovo farmaco di associazione |
| US20070207116A1 (en) * | 2006-03-01 | 2007-09-06 | Brown David C | Antioxidant compositions for the eye |
| ITMI20062134A1 (it) * | 2006-11-08 | 2008-05-09 | Cbb Net S A | Preparaziobne di esteri della diacereina con acido ialuronico e loro formulazioni per l'impiego farmaceutico |
| US8865685B2 (en) * | 2011-06-30 | 2014-10-21 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
| CA2886115A1 (en) * | 2012-10-02 | 2014-04-10 | Allergan, Inc. | Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes |
-
2016
- 2016-04-06 MA MA041912A patent/MA41912A/fr unknown
- 2016-04-07 WO PCT/IB2016/051960 patent/WO2016162809A1/en not_active Ceased
- 2016-04-07 JP JP2018503836A patent/JP6847091B2/ja not_active Expired - Fee Related
- 2016-04-07 RU RU2017138283A patent/RU2726192C2/ru active
- 2016-04-07 AU AU2016244391A patent/AU2016244391B2/en not_active Ceased
- 2016-04-07 BR BR112017021608A patent/BR112017021608A2/pt not_active IP Right Cessation
- 2016-04-07 CN CN201680025075.2A patent/CN107636020A/zh active Pending
- 2016-04-07 KR KR1020177032142A patent/KR20180002674A/ko not_active Ceased
- 2016-04-07 CA CA2981861A patent/CA2981861A1/en not_active Abandoned
- 2016-04-07 ES ES16726940T patent/ES2888648T3/es active Active
- 2016-04-07 EP EP16726940.6A patent/EP3280396B1/en active Active
- 2016-04-07 US US15/564,994 patent/US10328097B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3280396A1 (en) | 2018-02-14 |
| AU2016244391A1 (en) | 2017-11-23 |
| JP2018510962A (ja) | 2018-04-19 |
| CA2981861A1 (en) | 2016-10-13 |
| ES2888648T3 (es) | 2022-01-05 |
| AU2016244391B2 (en) | 2020-11-19 |
| US10328097B2 (en) | 2019-06-25 |
| CN107636020A (zh) | 2018-01-26 |
| RU2017138283A (ru) | 2019-05-07 |
| MA41912A (fr) | 2018-02-13 |
| WO2016162809A1 (en) | 2016-10-13 |
| JP6847091B2 (ja) | 2021-03-24 |
| RU2017138283A3 (cg-RX-API-DMAC10.html) | 2019-09-30 |
| EP3280396B1 (en) | 2021-06-23 |
| RU2726192C2 (ru) | 2020-07-09 |
| US20180117077A1 (en) | 2018-05-03 |
| KR20180002674A (ko) | 2018-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001270A (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39. | |
| BR112019000327A8 (pt) | Anticorpo para anticlaudina 18a2 e uso do mesmo | |
| MX2017012380A (es) | Derivados de maitansinoide, conjugados de los mismos, y metodos de uso. | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
| BR112016002233A2 (pt) | composições de adoçante | |
| BR112016014293A2 (pt) | região de fragmento cristalizável canino, anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, e, método para aumentar a atividade de uma célula imune | |
| BR112021022514A2 (pt) | Conjugados de anticorpo e fármaco | |
| BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| MX382518B (es) | Antigenos de citomegalovirus y su uso. | |
| BR112017023872A2 (pt) | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos | |
| CR20170259A (es) | Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
| BR112018012262A2 (pt) | composições de interleucina-15 e seus usos | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| BR112016029842A2 (pt) | conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos | |
| BR112017016897A2 (pt) | cepas fúngicas e métodos de uso | |
| BR112016023729A2 (pt) | espelho de veículo e método para a fabricação de tal espelho | |
| CO7170174A2 (es) | Formulación farmacéutica | |
| BR112018002427A2 (pt) | terapias de combinação para tratamento do câncer | |
| BR112016013800A2 (pt) | Composições e métodos para reduzir alérgenos de gatos no ambiente | |
| BR112017015452A2 (pt) | formulação farmacêutica | |
| BR112016022214A2 (pt) | rnase para uso no tratamento ou prevenção de infecções virais |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2717 DE 31-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |